



Corrigendum: RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

OPEN ACCESS

Edited and reviewed by:

Boris Zhivotovsky,
Karolinska Institutet (KI), Sweden

*Correspondence:

Qianjin Liao
march-on@126.com
Yujuan Zhou
yujany_zhou@163.com

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

Received: 26 May 2020

Accepted: 02 June 2020

Published: 14 July 2020

Citation:

Tan S, Yi P, Wang H, Xia L, Han Y,
Wang H, Zeng B, Tang L, Pan Q,
Tian Y, Rao S, Oyang L, Liang J, Lin J,
Su M, Shi Y, Liao Q and Zhou Y (2020)
Corrigendum: RAC1 Involves in the
Radioresistance by Mediating
Epithelial-Mesenchymal Transition in
Lung Cancer. *Front. Oncol.* 10:1106.
doi: 10.3389/fonc.2020.01106

Shiming Tan^{1†}, Pin Yi^{1,2†}, Heran Wang^{1,3}, Longzheng Xia¹, Yaqian Han¹, Hui Wang¹,
Biao Zeng¹, Lu Tang^{1,2}, Qing Pan^{1,2}, Yutong Tian^{1,2}, Shan Rao¹, Linda Oyang¹,
Jiixin Liang¹, Jinguan Lin¹, Min Su¹, Yingrui Shi¹, Qianjin Liao^{1*} and Yujuan Zhou^{1*}

¹ Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ² Hunan Cancer Hospital, University of South China, Hengyang, China, ³ Hepatology Unit, Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China

Keywords: RAC1, lung cancer, radioresistance, epithelial-to-mesenchymal transition, metastasis

A Corrigendum on

RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

by Tan, S., Yi, P., Wang, H., Xia, L., Han, Y., Wang, H., et al. (2020). *Front. Oncol.* 10:649.
doi: 10.3389/fonc.2020.00649

The authors regret that there was an error in **Figure 6** due to incorrect image editing in **Figure 6C**. The correct **Figure 6** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Tan, Yi, Wang, Xia, Han, Wang, Zeng, Tang, Pan, Tian, Rao, Oyang, Liang, Lin, Su, Shi, Liao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 6 | The effects of RAC1 expression in radiotherapy *in vivo*. **(A)** Representative photo of residual tumor of after 3*5 Gy dose of irradiation. **(B)** The time course of growth of Vector, RAC1, sh-control and sh-RAC1 xenograft tumors with or without IR treatment. **(C)** IHC staining showed an elevated Ki67 expression and upregulation of RAC1 in RAC1 overexpression xenograft tumor, which represents the radioresistant process in RAC1 overexpressing cells *in vivo*. Right panel showed a decreased Ki67 expression and downregulation of RAC1 in silencing RAC1 xenograft tumor, which represents the radiosensitivity process in sh-RAC1 cells *in vivo*. Down panel showed the quantification of scoring of immunostaining in RAC1 overexpression/silencing xenograft. Scale bar 100 μ m. Data are expressed as the mean \pm SD of different groups of cells from three separate experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.